Nykode Therapeutics posts new press release on VB10.NEO data update

(AWP Alliance News) - Nykode Therapeutics published a press release on July 22, 2026, outlining new preclinical and clinical updates for its individualized neoantigen therapy VB10.NEO. The company highlighted manufacturing optimization that cuts turnaround time to under six weeks. It also reported durable immunogenicity across two trials, with vaccine-specific immune responses in 88%-100% of patients. The release is available at https://nykode.com/research-and-development/sci…

NYKD: Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO

Nykode showcases its Individualized Neoantigen Therapy (INT), VB10.NEO, at theNeoantigen SummitThe data underscores the strengths of Nykode's differentiated APC-targetingand DNA-based INTNew data demonstrates substantial enhancement of immune response byco-administration of molecular adjuvantsFurther optimization of the manufacturing process reduces currentturnaround-time to less than 6 weeks with a clear path to further reductions byadditional consolidation under "one roof"N…

NYKD: Financial calendar

Financial calendar for Nykode Therapeutics ASAFINANCIAL YEAR 202525.02.2026 - Quarterly Report - Q4FINANCIAL YEAR 202626.08.2026 - Half-yearly Report17.04.2026 - Annual Report13.05.2026 - Annual General Meeting27.05.2026 - Quarterly Report - Q125.11.2026 - Quarterly Report - Q324.02.2027 - Quarterly Report - Q4This information is published pursuant to the requirements set out in theContinuing obligations.

Nykode Therapeutics to Present Interim VB-C-03 Trial Data at ICHNO 2026

(AWP Alliance News) - Nykode Therapeutics AS announced that it will present interim data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026. The results have not yet been presented. https://www.publicnow.com/view/50083614BCAF855F1059B44816C2D18AC7682E62/117424 Disclaimer: This news brief was created using generative artificial intelligence. Nykode Therapeutics AS published the original content u…

Nykode Therapeutics to Present Interim VB-C-03 Trial Data at ICHNO Conference

(AWP Alliance News) - Nykode Therapeutics ASA will present interim data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026. The VB-C-03 trial is evaluating abi-suva in combination with KEYTRUDA(R) (pembrolizumab) for the treatment of first-line unresectable recurrent or metastatic head and neck cancer. https://www.publicnow.com/view/DD6DDA6D406EB93F890B82D51F3EDACCE390E0F7/117424 Disclaimer: Thi…

NYKD: Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026

Oslo, Norway, December 19, 2025 - Nykode Therapeutics ASA (OSE: NYKD), aclinical-stage biopharmaceutical company dedicated to the discovery anddevelopment of novel immunotherapies, today announced the oral presentation ofinterim data from the VB-C-03 trial at the 10th International Congress onInnovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026.The VB-C-03 trial is investigating abi-suva in combination with KEYTRUDA®(pembrolizumab) in 1st line unresectable …

Nykode Therapeutics Nominates New Chair

02:11 AM EST, 12/18/2025 (MT Newswires) -- Nykode Therapeutics (NYKD.OL) said Thursday that Barbara Krebs-Pohl was nominated for the chair position. Krebs-Pohl, who will succeed interim Chair Susanne Stuffers, will be put forward for election at the clinical-stage biopharmaceutical company's extraordinary general meeting on Jan. 21, 2026. Nykode Therapeutics added that Stuffers will remain as a board member.

Nykode Therapeutics Names Dr. Barbara Krebs-Pohl Chair and Dr. John Beadle to Board

(AWP Alliance News) - Nykode Therapeutics AS has announced the nomination of Dr. Barbara Krebs-Pohl as the new Chair of the Board and Dr. John Beadle as a new board member. https://www.publicnow.com/view/6845B78B9C42BADF405FFD97CCB9D5706F728539/117424 Disclaimer: This news brief was created using generative artificial intelligence. Nykode Therapeutics AS published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the inf…

NYKD: Nykode Therapeutics Strengthens Board with the Nomination of Dr. Barbara Krebs-Pohl as New Chair of the Board and Dr. John Beadle as Board Member

o New board appointments support Nykode's strategic focus and advancing clinicalprioritieso Dr. Barbara Krebs-Pohl brings extensive global partnering and biotechleadership experienceo Dr. John Beadle adds deep expertise in immunotherapy technologies,translational oncology and drug development in generalo Susanne Stuffers to continue as Board memberOslo, Norway, December 18, 2025 - Nykode Therapeutics ASA (OSE: NYKD), aclinical-stage biopharmaceutical company dedicated to the …

Nykode Therapeutics ASA - Notice of Extraordinary General Meeting

Oslo, Norway, December 18, 2025 - The Board of Directors of Nykode TherapeuticsASA (OSE: NYKD) hereby calls for an Extraordinary General Meeting (EGM) to beheld at meeting room VIA - Building G, Floor 0 in Gaustadalléen 21, Oslo, Norwayat 10:00 CET on January 21, 2026.The purpose of the meeting is to elect a new Chair of the Board and additionalBoard members, including the current interim Chair of the Board.The notice of the EGM is attached. All documents regarding the EGM wi…

Nykode Therapeutics · 2024 financial report

Nykode Therapeutics · 2024-Q3 financial report

Nykode Therapeutics · 2024-Q2 financial report

Nykode Therapeutics · 2024-Q1 financial report